Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors

ConclusionFollowing 1L EGFR-TKI treatment, 19% of patients were tested for EGFR T790M, and most (69%) had no record of receiving any subsequent therapy.

http://link.springer.com/10.1007/s12325-020-01221-4

Source: Advances in Therapy - January 17, 2020 Category: Drugs & Pharmacology Source Type: research